Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 3-33 (IGHV3-33)
- Target
- IGHV3-33
- Molecular classification
- Other, Immunoglobulin variable region, Immunoglobulin family
01
Overview
Immunoglobulin heavy variable 3-33 (IGHV3-33) encodes the variable region of the heavy chain of immunoglobulins (antibodies), specifically participating in the antigen recognition domain of the antibody molecule[1][3][7]. IGHV3-33 contributes, through genetic recombination and somatic hypermutation, to the antibody diversity essential for adaptive immune responses. The gene is one of many in the IGHV locus, located on human chromosome 14 (14q32.33), and participates in V-(D)-J rearrangement in B lymphocytes to generate functional immunoglobulin heavy chains. Though IGHV3-33 is vital to immune diversity, it is not itself a conventional "therapeutic target" like enzymes or receptors—it serves a structural and coding role in the immune system's antibody repertoire. Variations in IGHV genes, including IGHV3-33, underlie differences in immune responses between individuals and populations and have been used in the study of immune system disorders and B cell malignancies, but drugs do not directly target IGHV3-33[1][2][3][4][7].
- Other names
- IGHV3-33Ig heavy chain V-III region HILIg heavy chain V-III region KOLIGHV333VHImmunoglobulin heavy chain variable region
02
Biological functions
Antigen bindingImmune response (specifically humoral/adaptive immunity)Formation of immunoglobulin (antibody) binding siteSomatic recombination (V-(D)-J rearrangement in B cells)
03
Disease associations
Other (Genetic diversity and variants in IGHV3-33 can be associated with altered immune repertoires, impacting susceptibility or response in infections, autoimmunity, and antibody-related cancers, but it is not a direct causal target)Cancer (implicated in B cell malignancies as part of the immunoglobulin repertoire)Infection (part of general immune response; some IGHV alleles are associated with response to pathogens, but no unique disease specificity for IGHV3-33 itself)
04
Biomarkers
Used as a marker in immunoglobulin gene rearrangement studies for B cell lineage (not disease-specific)Used in highly detailed immunogenetic profiling of B cell neoplasms for clonality assessment and minimal residual diseaseVariant usage (IGHV3-33 alleles) can be a biomarker for immune repertoire diversity and selection in immune monitoring
Beyond the preview
Go deeper on Immunoglobulin heavy variable 3-33 (IGHV3-33).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin heavy variable 3-33 (IGHV3-33).